AlphAIAlphAI — Financial news for AI agents
investing.com

Why is Glaukos stock surging today?

Glaukos stock surged 15.8% in pre-market trading after reporting Q3 2026 revenue of $211.03M, exceeding estimates by 25%, and adjusted EPS of $0.47, reversing an expected loss. The company raised full-year 2026 guidance to $775–$785M and introduced a preliminary 2027 target of $1B. Analysts increased price targets, citing strong performance of Epioxa and iDose TR. The stock broke its 52-week high, trading at $210.10.

Original reporting
investing.com
Published Oct 29, 2026, 11:44 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 29, 2026, 11:55 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefEarnings
Primary signal
MARKET
Neutral
AI market analysis
Mentioned
$GKOS
Relevance
9/10
AlphAI data visualization · based on investing.com
Decision brief

The 30-second read

High
01

Why it matters

The earnings surprise and guidance raise are likely to keep the stock in focus for the next trading sessions.

02

Market read

A strong earnings beat and guidance lift for Glaukos stands out in a risk‑off environment, offering a clear trade catalyst.

03

What to watch

Potential regulatory scrutiny of corneal cross‑linking therapy and reliance on a limited product portfolio.

Relevance 9/10Novelty 9/10Timing: pre‑market today

Background

Glaukos' earnings beat came despite a broader market decline in tech stocks.

Market effects

Sector

Boosts outlook for ophthalmology and corneal health device sector.

Regional

Positive for US biotech/medical device stocks amid broader risk‑off market.

Global

Highlights growth potential in eye‑care market worldwide.

Counterpoint

What could challenge this read

The surge may be overstated if future product adoption slows or competition intensifies.

Key entities

  • Executive
    Thomas Burns

    CEO of Glaukos who highlighted growth drivers iDose TR and Epioxa.

Read at source← All news

StoryGlaukos reports record Q3 sales, beats expectations and lifts 2026‑2027 revenue outlook

Also covered by

5 outlets

Related articles

$MGRCMed

McGrath RentCorp Soars 9% as It Prepares to Join the S&P SmallCap 600

McGrath RentCorp (MGRC) shares rose 9% on Monday after being added to the S&P SmallCap 600 index. The company cut its revenue outlook last week and is increasing capital expenditure. S&P SmallCap 600 index funds must buy MGRC shares by November 4. Glaukos (GKOS) and Loar Holdings (LOAR) are also being added to the S&P MidCap 400 and S&P SmallCap 600, respectively.

finance.yahoo.com
$GKOSHighAI 9/10

Glaukos (GKOS) Stock Soars After Blowout Q3 Earnings Beat

Glaukos (GKOS) stock surged 33.65% after Q3 earnings beat expectations, reporting EPS of $0.47 vs. -$0.09 and revenue of $211M vs. $168.1M. The company raised FY26 and FY27 revenue guidance, citing strong performance of iDose TR and Epioxa. Analysts upgraded price targets, with BTIG at $205 and Mizuho at $190.

timothysykes.com
$GKOSHighAI 8/10

Glaukos (GKOS) Stock Surges After Massive Earnings Beat

Glaukos (GKOS) stock surged 32.57% on October 29, 2026, after reporting Q3 revenue of $211M (vs. $168M expected) and adjusted EPS of $0.47 (vs. projected loss). The company raised its 2026 revenue guidance to $775M–$785M and 2027 to $1.0B. Positive clinical data for iDose TR and Epioxa, along with a retinal deal, supported the rally. GKOS closed at $240.52, up from $181.43 the prior day. Analysts raised price targets, with BTIG at $205 and Mizuho at $190.

stockstotrade.com
$GKOSHighAI 9/10

Glaukos (GKOS) Stock Surges After Earnings Beat And Bullish Guidance

Glaukos (GKOS) stock surged 32.65% after reporting Q3 earnings that beat expectations, with adjusted EPS of $0.47 vs. an expected loss. Revenue was $211M, exceeding the $168M consensus. The company raised its 2026 revenue guidance to $775M–$785M and set a 2027 target of $1.0B. Analysts maintained buy ratings with adjusted price targets.

timothysykes.com
$GKOSMedAI 8/10

Piper Sandler raises Glaukos stock price target on Epioxa strength

Piper Sandler raised its price target on Glaukos (GKOS) to $240 from $195, citing strong Q3 results. Revenue was $211.0M, up 58% YoY, beating estimates. The company also raised its fiscal 2026 revenue guidance to $775M-$785M. GKOS stock has surged 135% over the past year, trading near its 52-week high at $229.12. Other analysts also raised price targets, citing strong performance and pipeline progress.

investing.com